Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Jeff Stier

Jeff Stier, Associate Director, American Council on Science and HealthAssociate Director
American Council on Science and Health
Member of the Policy & Economics Council

Jeff Stier is an Associate Director at the American Council on Science and Health, a public health and consumer advocacy organization dedicated to promoting sound science in public health. In this position, he is responsible for government relations, policy, legal affairs and development. Mr. Stier specializes in food safety and nutrition (restaurant, agriculture, food and beverage industries), environmental health (chemical industry), pharmaceuticals and crisis communications regarding these industries. Additionally, he is an expert in class action litigation related to public health issues, regulatory and legal reform, tobacco policy and public health policy. Mr. Stier closely follows policies, legislations and regulations with the FDA, EPA, and USDA. He is often called upon to evaluate legal and regulatory matters related to specific health issues. Previously, Mr. Stier worked both in the office of the Mayor and in Corporation Counsel's office in the Giuliani administration in New York City. His responsibilities included planning environmental agency programs, legal analysis of proposed legislation, and health policy. His publications include “Bitter pill for FDA: law on herbal supplements,” “EPA Should Follow FDA's Bold Initiative,” “Big Tobacco Never Told the Truth,” “Drug Pipeline Gets Clamped by Jittery FDA,” “Drug Imports: A Prescription for Danger?” and “Trans Fat Ban's Economic Impact, from Fries to Soybeans.” (This is me - Update Profile)


Employment History
1997 - present Associate Director
American Council on Science and Health

GLG NewsSM Analyses by Jeff Stier(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Will The New Push To Limit DTC Advertising Advance? | 05-08-2008
Analysis of: New Rules on Drug Ads Sought | online.wsj.com
Author: Jeff Stier, Associate Director, American Council on Science and Health

Billions of dollars in pharmaceutical revenue, a large chunk of the advertising industry, and public health implications are at stake as Congress once again considers stricter limits on direct to consumer (DTC) advertising.

Generic Biologics Won't Get A Free Ride | 04-30-2008
Analysis of: Don't compromise the safety of biotech drugs | www.latimes.com
Author: Jeff Stier, Associate Director, American Council on Science and Health

Allowing "generic" versions of biotech drugs to market without full safety testing would endanger consumers

Good News on the Horizon for Pharmaceuticals | 02-25-2008
Analysis of: Justices Shield Medical Devices From Lawsuits | www.nytimes.com
Author: Jeff Stier, Associate Director, American Council on Science and Health

The decision on medical devices is good news for pharmaceuticals. If medicines get the same protection -- it could bode well -- for reasons beyond the obvious.

Regulatory Change Could Mean Millions to Big Pharma | 02-19-2008
Analysis of: F.D.A. Seeks to Broaden Range of Use for Drugs | www.nytimes.com
Author: Jeff Stier, Associate Director, American Council on Science and Health

A proposed regulatory change proposed on the Friday before a holiday weekend could have a major impact on pharmaceutical profits (and consumer health).

View All GLG News SM Analyses by Jeff Stier

GLG InstituteSM Seminars with Jeff Stier(?)

 
Jeff Stier has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Legal, Economic & Regulatory Affairs

Request a project with Jeff Stier








GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics